Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...89101112131415161718...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Crysvita (burosumab) / Ultragenyx, Kyowa Kirin, Voxzogo (vosoritide) / BioMarin
    Review, Journal:  NOVEL TREATMENT OPTIONS IN CHILDHOOD BONE DISEASES. (Pubmed Central) -  Dec 7, 2023   
    Burosumab is more etiology-based and convenient in comparison to conventional treatment of X-linked hypophospha--temic rickets in children and adults. Vosoritide importantly changes the natural course of achondroplasia, at least in the short term.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Follow-up imaging of SAPHO syndrome treated with denosumab. (Pubmed Central) -  Dec 4, 2023   
    Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Jun 2025 --> Nov 2026 No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Current indications for denosumab in benign bone tumours. (Pubmed Central) -  Dec 1, 2023   
    Data are derived, however, mostly from case reports and case series. Large prospective clinical trials are needed to evaluate the role and also the side effects of denosumab in the treatment of these rare diseases.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Osteonecrosis of the jaw under palbociclib: A case series description. (Pubmed Central) -  Nov 30, 2023   
    Denosumab may be recommended for patients with RA treated with csDMARDs to increase BMD and improve bone microarchitecture. We did not identify a specific pattern that could suggest a triggering role of palbociclib in the development of ONJ.
  • ||||||||||  ATI-2231 / Aclaris
    Enrollment change, Trial withdrawal:  ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov) -  Nov 29, 2023   
    P1,  N=0, Withdrawn, 
    We did not identify a specific pattern that could suggest a triggering role of palbociclib in the development of ONJ. N=36 --> 0 | Suspended --> Withdrawn
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Identification of Key Osteoporosis Genes Through Comparative Analysis of Men's and Women's Osteoblast Transcriptomes. (Pubmed Central) -  Nov 27, 2023   
    Denosumab treatment in postmenopausal women down-regulated 6 key genes, up-regulated T cell proportions, and down-regulated fibroblast proportion...We identified 9 key osteoporosis genes by comparing the transcriptome of osteoblasts in women and men. Our findings' clinical implications were confirmed by multi-omics data and qRT-PCR, and our study provides novel biomarkers and therapeutic targets for osteoporosis diagnosis and treatment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial primary completion date:  DEFENCE: Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (clinicaltrials.gov) -  Nov 22, 2023   
    P2,  N=8, Active, not recruiting, 
    Similar pathways could be adopted and tested in other centers. Trial primary completion date: Jul 2024 --> Sep 2023
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Trial completion, Trial completion date:  Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users (clinicaltrials.gov) -  Nov 21, 2023   
    P4,  N=70, Completed, 
    DEXA screening, and treatment with oral bisphosphonates is cost-effective if they reduce the PPF rate by just 0.6%. Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2023
  • ||||||||||  ATI-2231 / Aclaris
    Trial suspension, Metastases:  ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov) -  Nov 19, 2023   
    P1,  N=36, Suspended, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2023 Not yet recruiting --> Suspended
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management. (Pubmed Central) -  Nov 17, 2023   
    Since impaired bone formation represents the main mechanism by which GCs negatively affect skeletal health, osteoanabolic therapies appear to be pathophysiologically the more appropriate and appealing option, although cost considerations currently limit their use to selected severe cases. Regardless of the agent selected to mitigate the impact of GCs on the skeleton, what is most crucial is that the treating physician correctly stratifies the risk and intervenes at the right time.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal, Surgery:  Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis. (Pubmed Central) -  Nov 16, 2023   
    This network meta-analysis suggests that teriparatide combined with denosumab and teriparatide alone significantly increase the fusion rate and decrease the ODI without increasing adverse events. Based on current evidence, teriparatide combined with denosumab or teriparatide alone is recommended to increase the fusion rate and to reduce ODI in spinal fusion patients.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Current concepts in targeted therapies for benign tumors of the jaw - A review of the literature. (Pubmed Central) -  Nov 6, 2023   
    Targeted therapies decreased tumor size, slowed down tumor progression, and reduced bone pain. Surgery remains the gold standard, but targeted therapies are promising adjuvant or alternative treatment options for reducing tumor progression and morbidity of tumor surgery.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Outcomes following Stereotactic Radiotherapy in Oligometastatic Breast Cancer: a single centre retrospective review (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1611;    
    SABR for bony metastases from breast cancer has excellent local control rates in combination with systemic treatment but may also give patients significant time off treatment. Questions remain regarding the ideal sequencing and combination of SABR and SACT, particularly in hormone receptor positive patients where there are a number of lines of effective SACT.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Denosumab vs. Pamidronate in the Management of Osteolytic Bone Metastases Secondary to Breast Cancer, a Multi-Institutional Analysis. (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_564;    
    The results of this study showed that Denosumab had a statistically insignificant risk reduction in both pathological fracture (2.7% vs. 2.8%, p = 0.88) and spinal cord compression (2.6% vs. 2.7%, p = 0.88) and a statistically insignificant difference in the overall five-year survival rate (45.5% vs. 52.4%, p = 0.78) when compared to Pamidronate. As a result, additional factors such as financial cost, route of administration, dosing schedule, and potential adverse side effects should be discussed with each individual who requires pharmacological therapy for bone metastases secondary to breast cancer.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Impact of Discontinuation of Denosumab on Bone Health in Breast Cancer Patients (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_559;    
    It appears superior in reduction of SREs versus zoledronic acid (ZA) in established skeletal metastatic disease; thus, a preferred choice in the oncology setting...She was treated with neoadjuvant trastuzumab, pertuzumab, taxotere and carboplatin followed by bilateral mastectomy, and radiation to chest wall and L1...Bone modifying agents are often discontinued without consideration of the negative impact this may have. As this is a major survivorship issue, we document this case with literature review, to raise awareness for oncologists prescribing these medications.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Kanjinti (trastuzumab-anns) / Amgen, Daiichi Sankyo, AbbVie, Perjeta (pertuzumab) / Roche
    Germline mutation status of BRCA1/2 and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA) (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_450;    
    As this is a major survivorship issue, we document this case with literature review, to raise awareness for oncologists prescribing these medications. The trial randomized 780 patients twice to a total of 4 treatment groups (to receive or not receive denosumab; to receive nab-paclitaxel 125 mg/m2 weekly for 12 weeks or days 1 and 8 every 3 weeks for 4 cycles, both followed by 4 cycles of epirubicin/cyclophosphamide, 90/600 mg/m2 every 2 weeks/every 3 weeks according to the investigator
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis. (Pubmed Central) -  Nov 3, 2023   
    Further research is required to analyze denosumab's safety and efficacy and understand its local recurrence of GCTB, to identify the optimal dose. Future progress in this field will likely focus on exploring new diagnostic and recurrence markers to monitor disease progression and examine new therapeutic targets and treatment strategies.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Biomarker, Clinical, Observational data, Retrospective data, Review, Journal:  Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review. (Pubmed Central) -  Oct 31, 2023   
    Preoperative treatment with this drug is gaining increasing interest, as its high potency in tumor reduction in this subtype of neoplasm has allowed resectability in selected patients. We present the case of a young patient with a large spinal tumor who, after neoadjuvant Denosumab, underwent complete en bloc surgery with clean margins and a great pathological response.